Elastin Biosciences

Platform to Tackle Elastin Loss

About Us


Elastin Bioscience Company

Elastin Biosciences, a spin-out from Longaevus Technologies, is pioneering therapeutics that restore the body’s structural foundation.

By addressing extracellular matrix deterioration — a newly recognized hallmark of aging — we target a shared mechanism underlying cardiovascular, pulmonary, and dermal degeneration
.

What Is Elastin?
_____

Elastin, is one of the most dominant proteins in the body expressed in the:

Illustration of human lungs with bronchial tubes in purple.

Lungs

Illustration of a honeycomb structure above a honey jar with bees around it.

Skin

Outline of a person behind a fence with a dog.

Vascular System

The vast majority of elastin is deposited before adolescence, with synthesis essentially halting thereafter.

As We Age
___________

Elastin loss

Elastin degrades over time due to mechanical stress, chronic inflammation, UV damage and a wide variety of diseases.

This not only leads to loss of structural integrity. The by-products of elastin degradation are biochemically active and further drive the aging process.

A split image of a young woman and an elderly woman, with a transparent overlay highlighting the aging process.

Our Approach
______________

Elastin Restoration Platform

At Elastin Bioscienes, our team is developing an Elastin Restoration Platform to tackle elastin loss. Our approach develops a continuous pipeline of small molecules using cheminformatics, testing on human cells followed by testing on disease models of Elastin-related diseases.

Multiple clear purple test tubes arranged in a rack, with some filled with liquid, in a laboratory setting.

Pipeline
_______________

Our small molecule assets developed at Elastin Biosciences mark a new era in elastin research. These molecules are designed to not only boost elastin production but also to fortify the structural integrity of crucial tissues, particularly in the cardiovascular system.

In Vivo Success: Our research has yielded promising results beyond theoretical confines, showcasing significant increases in elastin expression and enhanced arterial strength in our in vivo studies.

A table listing therapeutic indications, asset IDs, proof-of-concept statuses, and development stages for cardiovascular and dermatology assets, with some cells marked as completed or ongoing.

Grants

A multinational EU-funded programme to develop a first-in-class treatment for Williams Syndrome.

WISER Consortium

Lead Institution: Elastin Biosciences

News

January 25, 2026

Milner Institute - Elastin Biosciences opens central lab at the Milner Institute in Cambridge


February 30, 2026

Milner Institute - Ecosystem Insights: Rihab Gam, Elastin Biosciences

Our Head of Biology gets the spotlight from the Milner Institute

September 30, 2025

University of Pennsylvania - ACE-ICRWS: Dual-Mechanism Therapy Reverses Vascular Aging

Presented at the International Conference on Research in Williams Syndrome, this talk detailed how our ElastoCure platform modulates critical genes to restore aortic health.

August, 1 2024

Lifespan.io - Targeting Williams and Marfan Syndromes

In this featured interview, CEO Sherif Idriss discusses the systemic rejuvenation observed in preclinical models, including improved mobility and vitality.

June 3, 2024

BioSpace - Elastin Biosciences Announces Positive Preclinical In Vivo Data Demonstrating Elastin Preservation and Restoration in Models of Abdominal Aortic Aneurysm and Williams Syndrome

September, 1, 2023

BioSpace - Elastin Biosciences Announces Breakthrough Discovery in Elastin Restoration: Paving the Way for Treatment of Elastin-Deficiency Diseases

Contact Us

Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!